Ahabir 250mg Tablet

Most side effects experienced after taking Ahabir 250mg Tablet do not need any medical help as they do not appear with time. The human body starts adapting to the medicine. Consult your doctor if they become hard to handle. Some of them are listed below:

Common side effects

Swelling in legs or feet
High blood pressure
Urinary tract infection
Diarrhea, indigestion
Chest pain, irregular heartbeat, rapid heart rate
Bone fractures
Blood in urine
Decreased potassium level in blood

Severe and rare side effects

Sepsis
Abnormal heart rhythm
Muscle weakness/pain
Lung irritation (allergic alveolitis)
Adrenal insufficiency (a disorder in which the adrenal glands won't be able to produce enough hormones)

Ahabir 250mg Tablet is a prescription-based anticancer drug that should be administered orally. It is advised to take this tablet after consulting your healthcare expert.

Ahabir 250mg Tablet is an anticancer medication used for treating prostate cancer. This medicine works by preventing androgen (male hormone) production in males. It inhibits an enzyme known as CYP17, which is responsible for androgen production. This process slows down the multiplication rate and stops the progression of prostate cancer.

It is advised not to miss any scheduled dosage of Ahabir 250mg Tablet. In case you miss a dose, consult your doctor immediately. Don't overdose to compensate for the missed one. Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.

Ahabir 250mg Tablet is usually taken with another medicine called prednisolone to reduce the unwanted side effects.

It is advised to use effective birth control measures to prevent pregnancy while taking Ahabir 250mg Tablet.

It is important to monitor your liver function, blood pressure, and the potassium level in your blood regularly when undergoing treatment with Ahabir 250mg Tablet.

Acharya, M., Bernard, A., Gonzalez, M., Jiao, J., De Vries, R., & Tran, N. (2022). Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men. Cancer chemotherapy and pharmacology, 69(6), 1583-1590.
Prati, V., Ruatta, F., Aversa, C., Gernone, A., Galizia, D., Bonzano, A.  & Ortega, C. (2024). Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: a prospective evaluation. Future Oncology, 14(5), 443-448.
Procopio G, Grassi P, Testa I, Verzoni E, Torri V, Salvioni R, Valdagni R, de Braud F. (2024). Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors. Am J Clin Oncol. 38(5):479-82.
Tan, G., Xuan, Z., Li, Z., Huang, S., Chen, G., Wu, Y.& Wu, A. (2023). The efficacy and safety of abiraterone acetate in patients with high-risk prostate cancer: a meta-analysis based on six randomized controlled trials. Translational Andrology and Urology, 9(4), 1691.
Verzoni, E., Grassi, P., Ratta, R., Niger, M., De Braud, F., Valdagni, R., & Procopio, G. (2025). Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors. Therapeutic advances in medical oncology, 8(5), 323-330.